TiumBio’s Post

Looking to automate and close your cell therapy workflow? Learn how to do just that – while increasing your efficiency – in this webinar. https://lnkd.in/gPzK4zBg #celltherapy #cellandgenetherapy #lifesciences #biotech

Looking to automate and close your cell therapy workflow? Learn how to do just that – while increasing your efficiency – in this webinar. https://lnkd.in/eJxwSi5p #celltherapy #cellandgenetherapy #lifesciences #biotech

Looking to automate and close your cell therapy workflow? Learn how to do just that – while increasing your efficiency – in this webinar. https://lnkd.in/eJxwSi5p #celltherapy #cellandgenetherapy #lifesciences #biotech

🔬 Insights into Optimal First-Line Seizure Medications for SCN8A from our recently published global modified Delphi consensus  Here, we highlight the optimal first-line treatments for those with seizures and Loss of Function (LOF) SCN8A variants. This graphic documents to first-line, most often effective treatments: Valproate, Ethosuximide, and Lamotrigine and advises caution with most Sodium Channel Blockers.   For more info about the newly published consensus and more practical insights on SCN8A, tailored for both families and clinicians, visit scn8aalliance.org.  #scn8a #scn8aawareness #scn8astrong #thisisscn8a #curescn8a #scn8aresearch #scn8aalliance #ndds #DEEs #neurodevelopmentaldisorders #clinicalresearch #clinicalcare

🔬 Insights into Optimal First-Line Seizure Medications for SCN8A from our recently published global modified Delphi consensus  Here, we highlight the optimal first-line treatments for those with seizures and Loss of Function (LOF) SCN8A variants. This graphic documents the first-line, most often effective treatments: Valproate, Ethosuximide, and Lamotrigine and advises caution with most Sodium Channel Blockers.   For more info about the newly published consensus and more practical insights on SCN8A, tailored for both families and clinicians, visit scn8aalliance.org.  #scn8a #scn8aawareness #scn8astrong #thisisscn8a #curescn8a #scn8aresearch #scn8aalliance #ndds #DEEs #neurodevelopmentaldisorders #clinicalresearch #clinicalcare

Would you like to explore multiple hypotheses at the same time? Roche can help. Their Digital LightCycler® dPCR System represents the next step in dPCR performance. By harnessing the power of this flexible, IT-connected system, you’ll have the potential to accelerate clinical advances with a variety of sample types—including FFPET, blood, or plasma. Learn more here: https://buff.ly/3Jyj2tD #DigitalPCR #pcr #qpcr

With passage of the first #GDUFA and #BsUFA in 2012, Congress helped ensure the FDA would have sufficient resources to carry out its mission. Learn how over 10 years of the #generics and #biosimilars program at the FDA have led to a dramatic increase in more affordable access to life-saving treatments for U.S. patients: https://lnkd.in/d_86mpDk

Have you ever wondered how your NIPT assay performs at critically low fetal fraction levels? Now you can find out thanks to our antepartum and postpartum reference materials which can be diluted to create various fetal fractions in order to assess your assay limit of detection (LoD) and complete a robust analytical validation. Find out more and order now at https://hubs.ly/Q02rJb9h0

JAKi and TYK2i: What/when to use? You can see that the JAKi/TYK2i have both approved or potential seropositive and seronegative indications. There are also improvements in PsO for the class and studies in CTDs. It is difficult to know which to choose

50 active RA pts RCT Rx w. either low dose IL-2(n=26), IL-2+TCZ (9) or control (15). All improved clinically by DAS28-ESR, but IL-2 Rx pts had signif proliferation of Tregs, w. decr inTh1, Th2, & Th17 cells. TREG #s correlated w/ ESR drop (r=0.54)